Chemoradiation Treatment for Head and Neck Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-04-30

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase II study of cetuximab, carboplatin and radiotherapy (RT) in patients with Locally Advanced Head and Neck Carcinomas (LAHNC) who are unfit for cisplatin.

The aim of this study is to show the feasibility and safety profile of the combination of cetuximab, carboplatin and RT in treatment of patients with LAHNC.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Chemotherapy, Radiation Therapy, and Cetuximab in Treating Patients With the Head and Neck Cancer

NCT00875849

Head and Neck Cancer

COMPLETED PHASE2

Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer

NCT00868491

Head and Neck Cancer

COMPLETED PHASE2

Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer

NCT00089297

Head and Neck Cancer

COMPLETED PHASE2

Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery

NCT00646659

Head and Neck Cancer

TERMINATED PHASE2

Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC)

NCT00904345

Head and Neck Cancer

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Secondary objectives are to estimate failure free survival (FFS) and overall survival, to evaluate the time to local and regional failure and to determine the site of first failure (characterised as local, regional, distant or combinations). Acute and late treatment toxicities will also be evaluated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Head and Neck Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single arm

Chemoradiation (Cetuximab, Carboplatin and Radiotherapy)

Group Type EXPERIMENTAL

Cetuximab

Intervention Type DRUG

Patients will receive weekly intravenous cetuximab (initial dose 400mg/m2 in the week prior to commencing radiotherapy, then weekly 250mg/m2)for the duration of the radiotherapy

Carboplatin

Intervention Type DRUG

Weekly intravenous carboplatin (AUC 2) for the duration of the RT

Radiotherapy

Intervention Type RADIATION

The radiotherapy schedule will be the "infield boost" (IFB) regimen, that is 66 Gy in 35 fractions over 5 weeks: daily for 3 weeks, then twice daily for 2 weeks (or 70 Gy in 35 fractions over 7 weeks for a specific subgroup of patients where IFB is not recommended).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cetuximab

Patients will receive weekly intravenous cetuximab (initial dose 400mg/m2 in the week prior to commencing radiotherapy, then weekly 250mg/m2)for the duration of the radiotherapy

Intervention Type DRUG

Carboplatin

Weekly intravenous carboplatin (AUC 2) for the duration of the RT

Intervention Type DRUG

Radiotherapy

The radiotherapy schedule will be the "infield boost" (IFB) regimen, that is 66 Gy in 35 fractions over 5 weeks: daily for 3 weeks, then twice daily for 2 weeks (or 70 Gy in 35 fractions over 7 weeks for a specific subgroup of patients where IFB is not recommended).

Intervention Type RADIATION

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Erbitux Paraplatin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Previously untreated SCC of the oropharynx, larynx or hypopharynx.
* Stage III or IV, excluding T1N1, and metastatic disease (to be confirmed by a chest CT, and abdominal CT or ultrasound scan if patients with abnormal liver function tests or a bone scan or FDG-PET if patients with bone pain).
* Histologically or cytologically confirmed HNSCC
* Disease must be considered potentially curable by chemoradiation
* Patients medically unfit for cisplatin chemotherapy due to one or more of the following reasons:

* Clinically significant sensori-neural hearing impairment (audiometric abnormalities without corresponding clinical deafness will not be regarded as a contraindication to cisplatin)
* Severe tinnitus
* Renal impairment (GFR \< 60ml/min)
* Peripheral neuropathy \> grade 2
* Inability to tolerate intravenous hydration eg due to cardiac disease
* Co-morbidities (based on clinical judgement by the investigator) associated with ECOG PS 2 that in the view of the investigator would preclude the safe administration of cisplatin
* Performance status ECOG 0, 1 or 2.
* Adequate haematological, renal and hepatic functions as defined by:

* Absolute neutrophil count (ANC, segmented cells (segs) + bands)\>= 1.5 x 109/L
* Platelet count \>= 100 x 109/L
* Total bilirubin \<= 1.5 x upper normal limit
* Alanine aminotransferase \<= 2.5 x upper normal limit
* Calculated creatinine clearance \> 40ml/min (Cockcroft-Gault formula).
* If calculated creatinine clearance \< 50 ml/min, glomerular filtration rate to be measured with DTPA or EDTA scan. If \< 40 ml/min not eligible.
* Age \>18 years
* Signed written consent
* Suitable for follow-up for 4 years in the view of the investigator

Exclusion Criteria

* Distant metastases, i.e., any metastatic disease below the clavicles. Patients with lung nodules \>10mm will be excluded unless non-malignancy aetiology is established. Patients with lesions 5-10mm can be included if a FDG-PET scan is negative and the investigator considers on clinical grounds that metastasis is unlikely. Patients with lesions \< 5mm can be included if the investigator considers on clinical grounds that metastases are unlikely. Patients with multiple lung nodules should not be included unless there is a strong case that these do not represent metastases, e.g., stable on imaging for over 12 months, non-malignant aetiology apparent. The level of clinical suspicion may be influenced by clinical stage, e.g., N3 disease, low neck nodes. In general if there is any doubt patients should be excluded.
* Previous radical RT to the head \& neck region, excluding superficial RT for a non-melanomatous skin cancer.
* Patients with prior cancers, except: those diagnosed \> 5 years ago with no evidence of disease recurrence and clinical expectation of recurrence of less than 5%; or successfully treated non-melanoma skin cancer; or carcinoma in situ of the cervix.
* Significant intercurrent illness that will interfere with the chemotherapy or radiation therapy such as HIV infection, cardiac failure, pulmonary compromise, active infection
* Any history of myocardial infarction, ventricular arrhythmias, or unstable angina within the last 6 months
* Pregnant or lactating women.
* Weight loss greater than 20 % of usual body weight in the 3 months preceding trial entry
* High risk for poor compliance with therapy or follow up as assessed by the investigator
* Prior radiation to greater than 30% of the bone marrow
* Prior systemic chemotherapy for cancer
* Refusal by male or female patients, to use appropriate contraception during the study and for 3 months afterwards
* Any condition or circumstance which might prevent the patient being able to give valid informed consent, or from completing participation in the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No